MicroRNAs regulate p21(Waf1/Cip1) protein expression and the DNA damage response in human embryonic stem cells. 2012

Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 3/A1, Brno, Czech Republic.

Studies of human embryonic stem cells (hESCs) commonly describe the nonfunctional p53-p21 axis of the G1/S checkpoint pathway with subsequent relevance for cell cycle regulation and the DNA damage response (DDR). Importantly, p21 mRNA is clearly present and upregulated after the DDR in hESCs, but p21 protein is not detectable. In this article, we provide evidence that expression of p21 protein is directly regulated by the microRNA (miRNA) pathway under standard culture conditions and after DNA damage. The DDR in hESCs leads to upregulation of tens of miRNAs, including hESC-specific miRNAs such as those of the miR-302 family, miR-371-372 family, or C19MC miRNA cluster. Most importantly, we show that the hESC-enriched miRNA family miR-302 (miR-302a, miR-302b, miR-302c, and miR-302d) directly contributes to regulation of p21 expression in hESCs and, thus, demonstrate a novel function for miR-302s in hESCS. The described mechanism elucidates the role of miRNAs in regulation of important molecular pathway governing the G1/S transition checkpoint before as well as after DNA damage.

UI MeSH Term Description Entries
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D050759 Cyclin-Dependent Kinase Inhibitor p21 A cyclin-dependent kinase inhibitor that mediates TUMOR SUPPRESSOR PROTEIN P53-dependent CELL CYCLE arrest. p21 interacts with a range of CYCLIN-DEPENDENT KINASES and associates with PROLIFERATING CELL NUCLEAR ANTIGEN and CASPASE 3. CDK2-Associated Protein 20 kDa,CDKN1 Protein,CDKN1A Protein,Cdk-Interacting Protein 1,Cdk2 Inhibitor Protein,Cell Cycle Regulator p21,Cyclin Kinase Inhibitor p21,Cyclin-Dependent Kinase Inhibitor 1A Protein,Senescent Cell-Derived Inhibitor Protein 1,p21 Cell Cycle Regulator,p21 Cyclin Kinase Inhibitor,CDK2 Associated Protein 20 kDa,Cdk Interacting Protein 1,Cyclin Dependent Kinase Inhibitor 1A Protein,Cyclin Dependent Kinase Inhibitor p21,Senescent Cell Derived Inhibitor Protein 1
D053595 Embryonic Stem Cells Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells. Stem Cells, Embryonic,Cell, Embryonic Stem,Cells, Embryonic Stem,Embryonic Stem Cell,Stem Cell, Embryonic
D060888 Real-Time Polymerase Chain Reaction Methods used for detecting the amplified DNA products from the polymerase chain reaction as they accumulate instead of at the end of the reaction. Kinetic Polymerase Chain Reaction,Quantitative Real-Time PCR,Quantitative Real-Time Polymerase Chain Reaction,Real-Time PCR,PCR, Quantitative Real-Time,PCR, Real-Time,PCRs, Quantitative Real-Time,PCRs, Real-Time,Quantitative Real Time PCR,Quantitative Real Time Polymerase Chain Reaction,Quantitative Real-Time PCRs,Real Time PCR,Real Time Polymerase Chain Reaction,Real-Time PCR, Quantitative,Real-Time PCRs,Real-Time PCRs, Quantitative
D020287 In Situ Nick-End Labeling An in situ method for detecting areas of DNA which are nicked during APOPTOSIS. Terminal deoxynucleotidyl transferase is used to add labeled dUTP, in a template-independent manner, to the 3 prime OH ends of either single- or double-stranded DNA. The terminal deoxynucleotidyl transferase nick end labeling, or TUNEL, assay labels apoptosis on a single-cell level, making it more sensitive than agarose gel electrophoresis for analysis of DNA FRAGMENTATION. Nick-End Labeling, In Situ,TUNEL,In Situ Nick End Labeling,In Situ Nick End Labelling,In Situ Nick End-Labeling,In Situ Nick End-Labelling,In Situ Nick-End Labelling,Nick End-Labeling, In Situ,Nick End-Labelling, In Situ,Nick-End Labelling, In Situ,Nick End Labeling, In Situ,Nick End Labelling, In Situ

Related Publications

Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
May 2020, Cells,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
June 1997, American journal of clinical pathology,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
October 2006, Liver international : official journal of the International Association for the Study of the Liver,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
December 2011, Experimental cell research,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
May 1996, Cancer research,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
April 2013, Cell death and differentiation,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
December 2007, FEBS letters,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
June 2008, Oncogene,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
March 2002, Carcinogenesis,
Dasa Dolezalova, and Marek Mraz, and Tomas Barta, and Karla Plevova, and Vladimir Vinarsky, and Zuzana Holubcova, and Josef Jaros, and Petr Dvorak, and Sarka Pospisilova, and Ales Hampl
March 2002, The Journal of biological chemistry,
Copied contents to your clipboard!